Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain

Journal of Pain and Symptom Management

Volumn 39, Issue 2, 2010, Pages 167-179

  Johnson, Jeremy R ^a   Burnell Nugent, Mary ^b   Lossignol, Dominique ^c   Ganae Motan, Elena Doina ^d   Potts, Richard ^e   Fallon, Marie T ^f  

^a Severn Hospice   (United Kingdom)

^b St Luke's Hospice   (United Kingdom)

^c JULES BORDET INSTITUTE   (Belgium)

^d Emergency Department   (Romania)

^e Porton Down Science Park   (United Kingdom)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cancer; cannabidiol; pain; Sativex ; tetrahydrocannabinol

Indexed keywords

CANNABIDIOL; ENDOCANNABINOID; OPIATE; PLACEBO; TETRAHYDROCANNABINOL;

ADULT; ADVANCED CANCER; ANALGESIA; ARTICLE; BRAIN METASTASIS; BRONCHOPNEUMONIA; CANCER PAIN; CANCER PATIENT; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DISORIENTATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTRIC ULCER BLEEDING; HEALTH CARE ORGANIZATION; HUMAN; HYPERGLYCEMIA; INTRACTABLE PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NAUSEA AND VOMITING; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SLEEP; SOMNOLENCE; STATISTICAL SIGNIFICANCE; SYNCOPE; THRUSH; TREMOR; VOMITING;

ADULT; AGED; CANNABIDIOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ENDPOINT DETERMINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PAIN, INTRACTABLE; TETRAHYDROCANNABINOL;

EID: 75949093107     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2009.06.008     Document Type: Article

References (45)

1. Glare P. Choice of opioids and the WHO ladder. In: Davis M., Glare P., and Hardy J. (Eds). Opioids in cancer pain (2005), Oxford University Press, Oxford, UK 221-234
2. Scottish Intercollegiate Guidelines Network. Control of pain in patients with cancer: A National Clinical Guideline (2000), SIGN 44, Edinburgh, Scotland 1-79
3. Cleeland C.S., Gonin R., Hatfield A.K., et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 330 (1994) 592-596
4. House of Lords Select Committee on Science and Technology. Cannabis: The scientific and medical evidence, 9th Report. Session 1997-98 (1998), House of Lords, London, UK. http://www.parliament.the-stationery-office.co.uk/pa/ld199798/ldselect/l dsctech/151/15101.htm Accessed January 4, 2008
5. ®, Ottawa, Canada (2007), Health Canada. http://cpe0013211b4c6d-cm0014e88ee7a4.cpe.net.cable.rogers.com/dpdonline /searchRequest.do Accessed March 4, 2008
6. Noyes R., Brunk S.F., Baram D.A., et al. Analgesic effect of delta 9-tetrahydrocannabinol. J Clin Pharmacol 15 (1975) 139-143
7. Noyes R., Brunk S.F., Avery D.A., et al. The analgesic properties of delta 9-tetrahydro-cannabinol and codeine. Clin Pharmacol Ther 18 (1975) 84-89
8. 2 receptors. Pharmacol Ther 74 (1997) 129-180
9. Pertwee R.G. Neuropharmacology and therapeutic potential of cannabinoids. Addict Biol 5 (2000) 37-46
10. Russo E.B., and Guy G.W. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabinol. Med Hypotheses 66 (2006) 234-246
11. Fride E., and Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol 231 (1993) 313-314
12. Thomas A., Baillie G.L., Phillips A.M., et al. Cannabidiol displays unexpectedly high potency as an antagonist of CB(1) and CB(2) receptor agonists in vitro. Br J Pharmacol 150 (2007) 613-623
13. Malfait A.M., Gallily R., Sumariwalla P.F., et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 97 (2000) 9561-9566
14. Hampson A.J., Grimaldi M., Axelrod J., and Wink D. Cannabidiol and (-)delta 9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 95 (1998) 8268-8273
15. Bisogno T., Hanus L., De Petrocellis L., et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134 (2001) 845-852
16. Carrier E.J., Auchampach J.A., and Hillard C.J. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA 103 (2006) 7895-7900
17. Pertwee R.G. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 147 Suppl 1 (2006) 163-171
18. Pertwee R.G. Cannabinoid receptors and pain. Prog Neurobiol 63 (2001) 569-611
19. Campbell F.A., Tamer M.R., Carroll D., et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systemic review. BMJ 323 (2001) 1-6
20. Jochimsen P.R., Lawton R.L., VerSteeg K., and Noyes R. Effect of benzopyranoperidine, a delta-9 THC congener, on pain. Clin Pharmacol Ther 24 2 (1978) 223-227
21. Staquet M., Gantt C., and Machin D. Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clin Pharmacol Ther 23 4 (1978) 297-401
22. McCormack H.M., Horne D.J., and Sheather S. Clinical applications of visual analogue scales: a critical review. Psychol Med 18 (1988) 1007-1019
23. Farrar J.T., Young Jr. J.P., LaMoreaux L., et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94 (2001) 149-158
24. Cleeland C.S., Ladinsky J.L., Serlin R.C., et al. Multidimensional measurement of cancer pain: comparisons of US and Vietnamese patients. J Pain Symptom Manage 3 (1988) 23-27
25. Aaronson N.K., Ahmedzai S., Bergman B., et al. The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality if life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 (1993) 365-376
26. Rog D.J., Nurmikko T.J., Friede T., et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 65 (2005) 812-819
27. Berman J.S., Symonds C., and Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 112 (2004) 299-306
28. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75 (1988) 800-802
29. Conover W.J., and Inam R.L. Analysis of covariance using the rank transformation. Biometrics 38 (1982) 715-724
30. Hodges Jr. J.L., and Lehmann E.L. Estimates of location based on rank tests. Ann Math Statist 34 (1963) 598-611
31. Johnson J.R., and Wright S.T. Cannabis-based medicines on the treatment of cancer pain: a randomised, double blind, parallel group, placebo controlled, comparative study of the efficiency, safety, and tolerability of Sativex and Tetranabinex in patients with cancer-related pain. J Support Oncol 3 Suppl 3 (2005) 21
32. Dworkin R.H., Turk D.C., Farrar J.T., et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 113 (2005) 9-19
33. Collin C., Davies P., Mutiboko I., et al. Randomised controlled trial of cannabis based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 14 (2007) 290-296
34. Wade D.T., Makela P., Robson P., et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 10 (2004) 1-8
35. Wade D.T., Makela P.M., House H., et al. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 12 (2006) 639-645
36. ® clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin Pharmacother 7 (2006) 607-615
37. Nurmikko T.J., Serpell M.G., Hoggart B., et al. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 133 (2007) 210-220
38. Rog D., Nurmikko T.J., and Young C.A. Oromucosal delta-9-tetrahrdrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther 20 (2007) 2068-2079
39. Ripamonti C., and Dickerson E.D. Strategies for the treatment of cancer pain in the new millennium. Drugs 61 (2001) 955-977
40. Russo E., Guy G., and Robson P. Cannabis, pain and sleep: lessons from therapeutic clinical trials of Sativex cannabis based medicine. Chem Biodivers 4 (2007) 1729-1743
41. Cox M.L., Haller V.L., and Welch S.P. Synergy between delta 9-tetrahydrocannabinol and morphine in the arthritic rat. Eur J Pharmacol 12 (2007) 125-130
42. Pertwee R.G. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: D9-tetrahydrocannabinol, cannabidiol and D9-tetrahydrocannabivarin. Br J Pharmacol 153 (2008) 199-215
43. In: Twycross R., Wilcock A., Charlesworth S., et al. (Eds). Palliative care formulary. 2nd ed (2002), Radcliffe Publishing, Oxford, UK
44. Fallon M. Opioid switching and rotation. In: Sykes N., Fallon M.T., and Patt R.B. (Eds). Clinical pain management: Cancer pain (2003), Hodder Arnold, London, UK 157-165
45. Hanks G., Cherney N., and Fallon M. The management of pain. In: Doyle D., Hanks G., Cherny N., and Calman K. (Eds). Oxford textbook of palliative medicine. 3rd ed (2005), Oxford University Press, Oxford, UK